Scientists say 40p worth of superfood every week can almost halve Alzheimer's risk
- Two studies published in JAMA Neurology found links between certain diabetes drugs and lower dementia risk.
- Rising rates of Alzheimer's and dementia globally prompted research into preventative measures for at-risk individuals.
- Researchers analyzed data from over 90,000 individuals, comparing GLP-1RAs and SGLT2is to other glucose-lowering treatments.
- One study showed GLP-1RAs reduced dementia risk by 33%, while SGLT2is showed a 43% reduction; Guo stated results are "very promising."
- These findings suggest GLP-1RAs and SGLT2is may offer neuroprotective benefits, but researchers call for further investigation.
23 Articles
23 Articles
γ-AApeptides–based Small Molecule Ligands That Disaggregate Human Islet Amyloid Polypeptide
The abnormal folding and aggregation of functional proteins into amyloid is a typical feature of many age-related diseases, including Type II diabetes. Growing evidence has revealed that the prevention of aggregate formation in culprit proteins could retard the progression of amyloid diseases. Human Amylin, also known as human islet amyloid polypeptide (hIAPP), is the major factor for categorizing Type II diabetes as an amyloid disease. Specific…
Ozempic may be linked to reduced risk of dementia
Diabetes and obesity drugs such as Ozempic have been shown to have many positive health effects. Can they also reduce the risk of dementia? The science room is also looking at a study on toxic blood and how the American research community is suffering cuts.
Coverage Details
Bias Distribution
- 73% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage